Dose calculation, design and development of nateglinide matrix tablets using quality by design approach and its pharmacokinetic evaluation in animal model

Ai M, Tanaka A, Ogita K, Shimokado K (2011) Favorable effects of early insulin secretion by nateglinide on postprandial hyperlipidemia in patients with type 2 diabetes. Diabetes Care 29:1180. doi: 10.2337/dc05-2336

Bhupinder S, Kumar R, Naveen A (2004) Optimizing drug delivery systems using systematic “Design of Experiments” Part I: fundamental aspects. Criti Rev Ther Drug 22(1):27–105. doi: 10.1615/CritRevTherDrugCarrierSyst.v22.i1.20

Brahmankar DM (2008) Biopharmaceutics and pharmacokinetics—a treatise, 2nd edn. Vallabh Prakashan, New Delhi, pp 343–350

Chisato M, Nobutaka N, Hidetoshi S, Haruo O, Akira O, Akira Y (2006) Effect of decrease in both postprandial blood glucose (PBG) and fasting blood glucose (FBG) levels in normal beagle dogs with nateglinide enteric coated granules and immediate release tablets. Chem Pharm Bull 54(4):409–414. doi: 10.1248/cpb.54.409

Dunn C, Faulds D (2000) Nateglinide. Drugs 60:607

Ferreira SLC, Bruns RE, Ferreira HS, Matos GD, David JM, Brandao GC (2007) Box-Behnken design: an alternative for the optimization of analytical methods. Anal Chim Acta 597(2):179–186. doi: 10.1016/j.aca.2007.07.011

Geoffroy JM, Fredrickson JK, Shelton JT (1998) A mixture experiment approach for controlling the dissolution rate of a sustained release tablet. Drug Dev Ind Pharm 24(9):799–806. doi: 10.3109/03639049809088524

Ghosh MN (2005) Fundamentals of experimental pharmacology, 3rd edn. Sk Ghosh Publications, Kolkata, pp 192–194

Gribble FM, Manley SE, Levy JC (2001) Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166). Diabetes Care 24(7):1221–1225. doi: 10.2337/diacare.24.7.1221

Grimm W (1998) Extension of the International Conference on Harmonisation Tripartite Guidelines for stability testing of new drug substances and products to countries of Climatic Zones III and IV. Drug Dev Ind Pharm 24:313–325. doi: 10.3109/03639049809085626

Hamed E, Sakr A (2001) Application of multiple response optimization technique to extended release formulation design. J Control Rel 73(2–3):329–338. doi: 10.1016/S0168-3659(01)00356-X

Higuchi T (1963) Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 52:1145–1149. doi: 10.1002/jps.2600521210

Hixson AW, Crowell JH (1931) Dependence of reaction velocity upon surface and agitation. I. Theoretical considerations. Ind Eng Chem 23:923–931

ICH (2003) Harmonised tripatite guideline: stability testing of new drug substances and products ICH Q1A(R2). ICH Expert Working Group, Europe, Japan and USA

Jaiprakash NS, Mrinmayee D, Rohidas A, Zaheer Z, Devanand BS (2014) Quality by design approach: regulatory need. Arabian J Chem. doi: 10.1016/j.arabjc.2014.01.025

Japanese Pharmacopoeia (2011) 16th edn, The Ministry of Health, Labour and Welfare Ministerial Notification 65:1148

Jolly MS, Mayur GS, Vijay BS, Rajashree CM (2007) Nateglinide quantification in rabbit plasma by HPLC: optimization and application to pharmacokinetic study. J Pharm Biomed Anal 44:196–204

Kolter K, Fraunhofer W, Ruchatz F (2001) Properties of Kollidon SR as a new excipient for sustained release dosage forms. BASF Ex Act 6:5

Korsmeyer R, Gurny R, Peppas N (1983) Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm 15(1):25–35. doi: 10.1016/0378-5173(83)90064-9

Lazarus J, Cooper J (1961) Absorption, testing and clinical evaluation of oral prolonged action drugs. J Pharm Sci 50:715–732. doi: 10.1002/jps.2600500902

Long W, Kitlun Y, Sunpui N, Joanne Y (2012) Application of the Box-Behnken design to the optimization of process parameters in foam cup molding. Expert Syst Appl 39(9):8059–8065. doi: 10.1016/j.eswa.2012.01.137

Makino C, Sakai H, Okano A, Yabuki A (2009) Design of nateglinide controlled release tablet containing erosion matrix tablet and multiple administration study in normal beagle dogs. Chem Pharm Bull 57:907–913. doi: 10.1248/cpb.57.907

McLeod JF (2004) Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. Clin Pharmacokinet 43(2):97–120

Montgomery DC (2001) Design and analysis of experiments, 5th edn. Wiley, New York

Peppas NA (1985) Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv 60:110–111

Porter SC, Verseput RP, Cunnigaham CR (1997) Process optimization using design of experiments. Pharm Technol 21:60–70

Shargel L, Wu-Pong S, Andrew BCY (1999) Applied Biopharmaceutics and pharmacokinetics, 6th edn. The McGraw Hill Companies, New York, pp 476–478

Tentolouris N, Voulgari C, Katsilambros N (2007) A review of nateglinide in the management of patients with type 2 diabetes. Vasc Health Risk Manag 3:797–807

Wagner JG (1969) Interpretation of percent dissolved-time plots derived from in vitro testing of conventional tablets and capsules. J Pharm Sci 58(10):1253–1257. doi: 10.1002/jps.2600581021